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Two small, placebo-controlled studies of immunotherapy with heat killed Mycobacterium vaccae added to routine 
chemotherapy for pulmonary tuberculosis, together involving 40 HIV seronegative patients, were carried out in 
Argentina. The immunotherapy was associated with reduced sputum smear positivity of AFB at 1 month and a 
greater reduction in ESR at 2 months. In the first study radiological improvement was better (PcO.05) among 
immunotherapy recipients. In the second study, weight regain and time to become apyrexial were measured and 
were found to be improved amongst immunotherapy recipients (PcO.05). 
In the first month of treatment the levels of IgG to the 65 kDa and 70 kDa heat-shock proteins showed greater 
falls following immunotherapy (PC O-05 and P<O*OOl, respectively). On admission serum cytokine levels of 
interleukins 4 and 10 (IL-4, IL-lo), interferon gamma (IFN-y) and tumour necrosis factor alpha (TNF-a) were 
grossly raised in comparison with a matched control group (P<O*OOl). After 1 month. Levels of IL-4, IL-10 and 
TNF-cu fell (P<O.OOl, P<O.Ol and PcO.01, respectively) and levels of IFN-?I rose more (P=O-005) in 
immunotherapy recipients than in those receiving chemotherapy alone. The results are in accord with a switch 
towards a THl immunological status and clinical benefit for immunotherapy recipients. 
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Introduction 
Two small studies of immunotherapy for tuberculosis with 
Mycobacterium vaccae (SRL 172) have been carried out at 
Carrasco Hospital in Rosario, Argentina. Both were pilot 
studies in small numbers of volunteer patients, but they 
illustrate well the potential value of immunotherapy added 
to chemotherapy for the disease and have led to some new 
findings. Both studies were placebo-controlled, randomized 
and partially blinded. It is the practice at Carrasco Hospital 
to keep patients in the wards for the first l-2 months of 
treatment and then to treat them on an outpatient basis. 
Patients have clinic appointments for the end of the second 
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month and at intermediate times to 6 months when 
chemotherapy is stopped. Out of hospital, their chemother- 
apy is not directly observed, though this changed to a full 
DOTS programme after our study was completed. Those 
failing treatment, or subsequently relapsing, usually return 
to the same hospital which is the major one dealing with 
tuberculosis in the city. Thus most patients with recurring 
disease are discovered. 
As well as clinical benefits, previous studies have shown 
an accelerated return to normal values of serum agalactosyl 
immunoglobulin (Gal [0]) following immunotherapy with 
M. vaccae in those in whom this marker of disease is 
initially raised (1). We have carried out a blinded study of 
the levels of IgG antibodies to the 65 kDa and 70 kDa heat 
shock proteins (hsp) of BCG, and of levels of tumour 
necrosis factor alpha (TNF-a), gamma interferon (IFN-y), 
interleukin 4 (IL-4) and interleukin 10 (IL-lo) in the serum 
of patients at the start of treatment and 1 month later. 
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Materials and Methods 
SUBJECTS 
These were 40 newly diagnosed HIV seronegative patients 
without previous histories of tuberculosis. Thirty-seven 
patients had pulmonary disease. One with pleural effusion, 
and three had miliary tuberculosis. In both studies the 
patients in the two treatment groups had very similar 
disease based on the amount of lung involvement and their 
clinical condition. All had acid-fast bacilli (AFB) demon- 
strable in their sputum by culture with the exception of one 
patient with miliary tuberculosis in whom the diagnosis was 
confirmed by biopsy and culture. All patients had the 
studies explained to them and agreed to participate. Except 
for the single injection of intervention and the saving of sera 
from routine venipunctures from some patients for 
immunological studies, procedures were those in standard 
use in the hospital. 
ETHICAL APPROVAL 
The studies were approved by the Ethical Committee of the 
Facultad de Ciencias Medicas, Universidad National de 
Rosario (on 1 July 1991 and 2 March 1994, respectively). 
INTERVENTION 
This consisted of a single intradermal injection of 0.1 ml of 
either immunotherapy or placebo given over the left deltoid 
muscle. The immunotherapeutic consisted of a suspension 
of heat-killed M. vaccae NCTC 11659 (SRL 172) batch A4 
containing 10 mg wet-weight of bacilli per ml of M/l5 
borate-buffered saline at pH 8.0, equivalent to lo9 bacilli 
per dose; the placebo was tetanus toxoid in the first study 
and physiological saline in the second study. In the first 
study (2) the injections were given 15 days after starting 
chemotherapy and in the second study they were given on 
the first day of chemotherapy. Injections were given by a 
physician who played no further part in the treatment of the 
patients. For the first study, 20 patients were allocated to 
receive the intervention in the ratio of one placebo to two 
immunotherapy. For the second study, in which 20 patients 
received intervention on day 1 of chemotherapy, patients 
were paired according to the severity and nature of their 
disease and a sealed envelope was opened to determine 
which intervention should be given to the first of each pair 
presenting for treatment. 
CHEMOTHERAPY 
Short-course chemotherapy was employed with daily 
isoniazid (H), rifampicin (R) and streptomycin (S) for 2 
months, followed by 4 months of H and R alone. In the first 
study three of 13 patients given immunotherapy and one of 
seven given placebo and all patients in the second study 
received pyrazinamide (Z) in addition. In both studies the 
prescribed continuation phase was 4 months of H and R 
alone (2HRS[Z]/4HR). Therapy was directly observed 
during the time that patients were in hospital but not 
thereafter. 
ROUTINE INVESTIGATIONS 
Symptomatic patients were admitted to hospital on 
production of a sputum sample with acid-fast bacilli visible 
on microscopy, or with a biopsy showing acid fast bacilli, 
and from which they could be cultured. 
Susceptibility tests were carried out on all initial cultures 
to the four drugs used and to ethambutol. Subsequently 
sputum samples were examined by microscopy after 1 
month and, if sputum could be produced, at outpatient 
visits. Blood samples were taken for routine heamatology 
and biochemistry at diagnosis and after 1 and 2 months. 
Laboratory staff did not know which patients had received 
which intervention, or even that the patients were in a 
study. Chest x-rays were routinely performed on admission, 
after 2 months and at the end of chemotherapy. Clinical 
observations of fever (37.5”C or more), cough, bodyweight 
etc. were recorded in the clinical notes, and data was 
extracted at the end of the studies. Recovery from pyrexia 
was followed by different parameters in the two studies. In 
the first study, time for pyrexia to resolve was measured and 
in the second study, numbers of patients showing resolution 
of fever at 2 weeks was the end-point. 
SPECIAL INVESTIGATIONS 
Serum samples were saved from venipunctures performed 
for routine investigations in the second study and samples 
taken at these times were available from the first study. The 
samples were stored at - 20°C and analysed together at the 
end of the study by an immunologist who did not know 
which intervention patients had received. Similarly, sets of 
x-rays were presented for analysis to an experienced chest 
physician blinded as to the intervention given. 
IMMUNOLOGICAL INVESTIGATIONS 
Serum samples taken at diagnosis and after 30 days of 
treatment were tested by the enzyme-lined immunosorbent 
assay (ELISA) for 1gG antibodies to the 65 kDa and 70 
kDa hsp of BCG; results were recorded as absorption 
values. The same serum samples were tested for IFN-y, 
TNF-LX, IL-4 and IL-IO, by ELISA using commercial kits 
(R&D Systems Ltd, Abingdon, U.K.) and results were 
calculated to pg per cm3 of serum. All samples were tested 
in duplicate at the same time, and following the manu- 
facturers instructions. Twelve healthy people of the same 
age range and living in the same area but not known to be 
in contact with tuberculosis patients provided control sera. 
STATISTICAL ANALYSES 
These were by student’s t-test the paired t-test and 
Wilcoxon’s test. 
TABLE 1. Initial parameters of the patients entering the two studies 
Immunomotherapy 
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Placebo 
Age (years) 
Smoke tobacco 
Drink alcohol 
AFB seen in sputum 
Number of bacilli 
Culture positive 
Colony count (2nd study only) 
Radiological evidence of disease 
Bilateral 
Unilateral 
Miliary 
Pleural 
ESR (mm) 
Data available from first study only 
Haemoglobin (g 1-l) 
White cell count 
Data available from second study only 
Body weight (kg) 
40.4f 12.3 
17/23 (74%) 
13/23 (57%) 
22123 
*o + ++ +++ 
211 6 3 
22123 
0 <20 <lOO 100-t 
14 3 2 
14/23 (61%) 
7/23 (30%) 
2123 
0 
80.8 * 34.0 
11.9f l-6 
8577f2101 
51.2+5.8 
n.s. 
39.4f 16.7 
13/17 (76%) 
12/17 (71%) 
15/17 
0 + ++ ++t 
18 4 2 
17/17 
0 <20 <lOO 100+ 
-4 5 1 
n.s. 13/17 (76%) 
n.s. 2/17 (12%) 
l/17 (71%) 
l/17 
n.s. 70.1+ 32.6 
n.s. 11*4+ 1.3 
n.s. 8964+3100 
n.s. 55*3&8-O 
*For several patients the numbers of acid fast bacilli seen in positive smears were not recorded. 
n.s. not significant. 
Results 
The mean age of those receiving immunotherapy was 
40*4_+ 12.3 years and of those receiving placebo it was 
39*0+ 16.7 years. In the first study, all subjects were men 
and in the second study three women received immunother- 
apy and one received placebo. The 30140 patients who were 
smokers and the 25140 who were alcohol drinkers were 
evenly distributed between intervention groups, as shown in 
Table. 1. The results of initial sputum bacteriology are also 
shown in Table 1. Strains from only two patients were 
recorded as showing drug resistance, one to streptomycin 
and the other to ethambutol. By chance, both of these came 
from the immunotherapy recipient group. 
Radiology at entry showed that of those receiving 
immunotherapy, 14 had bilateral disease, Seven had 
unilateral disease and two had miliary tuberculosis. Of 
those receiving placebo, 13 had bilateral disease. Two had 
unilateral disease, one had miliary and one had pleural 
tuberculosis. 
As shown in Table 2, after 1 month fewer patients 
receiving immunotherapy had AFB demonstrable in their 
sputum by smear @‘<O-025) but by 2 months only a few 
patients provided samples and results were similar for both 
groups. Radiological improvement was best amongst 
immunotherapy recipients at two months, but numbers 
were too few for statistical significance. The ESR of 80.8 
mm fell to 48.6 mm at 2 months in the M. vclccae group 
TABLE 2. The results of sputum smear examination at 
entry and after 1 and 2 months of treatment, of x-ray 
improvement after 2 months and of erythrocyte sedimenta- 
tion rate (ESR) at entry and after 2 months. Data have been 
pooled from both studies where this was compatable. 
Immunotherapy Placebo 
AFB visible in sputum 
Entry 22123 15/17 
1 month 3/21 (14%) P<O.O25 8/16 (50%) 
2 months l/7 218 
x-ray improvement by month 2 
Very good S/19 (P=O.ll) 2113 
Good* lOj19 9113 
Little of none l/19 2113 
ESR (mm) 
Entry 80.8 + 34.0 70.1 f 32.6 
P<O*OOl 
2 month 48.6f 35.8 62.8n:b3.4 
*For the radiological assessment, ‘good’ indicates that the 
patient’s response is similar to that usually seen in similar 
patients receiving chemotherapy alone ‘Very good’ infers 
that the patient has done better than expected. 
n.s. not significant. 
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(P<O*OOl), whereas that of the placebo group only fell 
from 70.1 to 62.8 mm (not significant). 
Bodyweights were not recorded longitudinally in the first 
study, but the second study showed that weight increases 
(from entry to day 30) were significant on paired t-test and 
Wilcoxon test in M. vuccae recipients (51.2k5.8 vs. 
54.8 + 5.9: PcO.05) but not in the placebo group 
(55.3+8 vs. 57.8_+ 10.4).In the first study resolution of 
pyrexia took 19 + 14 days for 11 immunotherapy recipients 
and 22 + 15 days for six placebo recipients. In the second 
study two of 10 M. vaccae recipients and seven of 10 in the 
placebo group remained febrile after 2 weeks (PcO.04; 
Fisher’s exact test). In the first study, when patients were 
discharged from hospital according to their clinical status 
those receiving immunotherapy left after 45*20 days. 
Whereas placebo recipients left after 60 + 15 days (P = 0.1). 
Table 3 shows the serological results. IgG to hsp 65 was 
marginally raised amongst the tuberculosis patients at the 
start of treatment and fell to normal in both groups by the 
end of 1 month. those receiving immunotherapy showing 
the greatest fall P-c 0.001). The IgG to hsp 70 was markedly 
raised above that of controls at the beginning of treatment 
and fell almost to normal within 1 month in the M. vaccae 
group and only slightly amongst placebo recipients 
(P<0.0001). 
All cytokine levels in the tuberculosis patients were 
markedly above those of the healthy controls at the start of 
treatment (P<O.OOl). within 1 month both treatment 
groups showed reductions in IL-4, IL-10 and TNF-a, and 
an increase in IFN-y, but in each case this was most marked 
amongst immunotherapy recipients (P-cO.02). 
Discussion 
Although our studies are of small numbers, they are the 
first published results of immunotherapy for South Amer- 
ican Patients. They include the first study of administration 
of M. vaccae on day 1 of chemotherapy and the first in 
which serum cytokines have been measured in relation to 
this. 
TABLE 3. Results of ELISA absorption measurements. k SE of IgG antibodies to heat shock proteins 65 kDa and 70 kDa 
and of the serum cytokines interleukin-4 (IL-4), interleukin-IO (IL-lo), interferon gamma (IFN-7) and tumour necosis factor 
alpha (TNF-cr) in pg/ml 
Immunotherapy Placebo 
hsp 65 k Da 
On admission 
After 1 month 
% decrease 
hsp 70 k Da 
On admission 
After 1 month 
% decrease 
IL-4 
On admission 
After 1 month 
% decrease 
IL-10 
On admission 
After 1 month 
% decrease 
IFN-y 
On admission 
After 1 month 
% increase 
TNF-a 
On admission 
After 1 month 
% decrease 
n=13 
0*30*0.03 
P<O*OOl 
0.19+0.02 
32k5.5 
o-59+0*05 
P<O.OOl 
0.31+0*03 
48f3-6 
685$77 
342+36 
47k4.7 
3800+302 
2292+_187 
38f5*3 
524&76 
1172f 173 
124+21 
86+6 
52+5 
38+3*6 
P-CO.05 
P<O*OOl 
P<0*0001 
P-CO.02 
P<O*OOl 
P-CO*002 
P<O*OO7 
P<O*O5 
P<O*OO5 
P<O*OOl 
P<O-01 
n=ll 
0.23*0-04 
P-CO.05 
0*2f0*02 
15.6k5.4 
0.62kO.06 
n.s. 
0.53kO.06 
17k2.6 
586+63 
495+58 
15+4.9 
3863_+270 
3663f286 
16.5k5.8 
553+57 
700+99 
41+20 
85.5k3.3 
74k3.7 
14+4*1 
Controls 
n=12 
0+20+0.04a 
0.25f0.06b 
69+9b 
35+6b 
157+7b 
none 
detectableb 
“Different from immunotherapy group. P < 0.02 
bDifferent from immunotherapy and placebo groups. P<O*OOl 
n.s., not significant. 
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With such small numbers of patients, few clinical 
differences between treatment groups could be expected to 
reach statistical significance. Nonetheless, the faster radi- 
ological improvement and discharge from hospital asso- 
ciated with immunotherapy in the first study, and the better 
weight regain and faster resolution of pyrexia in the second, 
do indicate patient benefit. Improved smear conversion at 1 
month suggests a public health benefit and greater fall in 
ESR indicates faster recovery from disease in those 
receiving M. vaccae. These results concur with those 
reported from studies of this immunotherapy in Nigeria 
(3), Romania (4), Uganda (5) and Vietnam but differ from 
those of a larger study carried out in South Africa (6). 
The serological results we describe are striking, with 
much greater changes occurring within the first month of 
treatment in the immunotherapy recipients than in those 
receiving placebo. The initially raised levels of IgG to the 70 
kDa stress protein and marginal increase in IgG to the 65 
kDa stress protein were particularly interesting, having 
been recorded in other diseases in which the immune system 
damages host tissues (7,8,9). It has long been known that a 
part of the pathology of tuberculosis is immunologically 
mediated. The rapid reduction in antibody to these stress 
proteins found to follow immunotherapy with M. vaccae 
accords with the better clinical and radiological response of 
these patients. 
Overall, the serum cytokine data on immunotherapy 
recipients makes a composite picture of regulation of the 
maturation pathways of T-helper (TH) cells in a way that 
also occurs though at a slower pace, in the placebo group. 
In tuberculosis, the toxicity of circulating TNF-a is 
thought to be responsible for fever, weight loss, raised 
ESR and death. TNF-a! does not have these effects except 
when raised levels of the type 2 cytokines, IL-4, IL-S, IL-10 
etc., are also present (10). Regulation of production of these 
cytokines could be achieved by reducing the proportion of 
TH2 cells maturing from stem cells, or by regulating their 
capacity to produce and release cytokines. The speed with 
which such changes occur after immunotherapy with M. 
vaccae suggests that it is the latter. In patients with a raised 
proportion of CD4+ T cells making IL-4, the first change in 
cytokine production found by flourescence-activated cyto- 
metry following a first injection of M. vaccae, is a reduction 
in this proportion within 2 weeks (II). This has been seen in 
patients with cancers (11) or with infections with opportu- 
nist mycobacteria (N. Thapa, personal communication). 
Down regulation of TH2 would be accompanied by a 
reduction in T-cell dependant antibody production but the 
rapid reduction in IgG to the stress proteins found in M. 
vaccae recipients suggests that such antibodies are being 
used up in the pathological lesions. Regulation of T-helper 
cell maturation is demonstrable in experimentally infected 
animals receiving injections of M. vaccae (12, 13). 
There are doubts about the levels of IL-4 circulating in 
tuberculosis but this may be due to different severities of 
disease (14) and it is possible that the technique is more a 
measure or rheumatoid factor than of IL-4. It is unfortu- 
nate that no serum remains for rheumatoid factor to be 
measured. Whatever the test measures, it represents some- 
thing changing faster in immunotherapy recipients than in 
those receiving placebo and is accompanied by a fall in IL- 
10, also indicating reduced TH2 activity. 
The lesser changes in stress protein antibody, TNF-(r and 
IL-4 levels in placebo recipients are an effect of the 
antituberculosis chemotherapy, most probably due to the 
rapid killing of bacilli. Live tubercle bacilli have been 
shown to produce a factor (TEA) increasing the activity of 
TNF-a which antagonises ACTH (15). This would modify 
the ratio of cortisone to dehydroepiandrosterone (DHEA) 
produced in the adrenals and secondarily regulate T-helper 
cell maturation (16). Additional control mechanisms could 
be through lesional macrophages changing local production 
of DHEA sulphatase and/or of enzymes regulating the 
cortisone-cortisol shuttle (17). There may also be direct 
effects of drugs such as rifampicin on macrophage function 
(18). 
The enhancement of THl in those receiving injections of 
M. vuccae appears to be a separate and slightly later effect, 
possibly reflecting the time required for cell maturation 
(11). M. vuccae is a potent stimulus for IL-12 production 
and enhanced THl maturation may be the response to this 
(19). (Tight control of the manufacturing process and 
various biochemical and immunological tests ensure that 
SRL 172 is produced consistently.) Injection of M. vaccae 
might also be expected to be a stimulus for the production 
of CD8+ cytotoxic T cells and this, as well as many other 
changes following injection of M. vaccae, have been shown 
in experimental animal models (12, 13, 19). 
Faster sputum smear convertion in immunotherapy 
recipients may be associated with increased IFN-7 produc- 
tion which, together with the greater reduction in IgG levels 
to the stress proteins, should enhance granuloma formation 
without tissue necrosis. Live tubercle bacilli are released 
into the airways to appear in the sputum as a result of the 
necrosis and liquefaction of lesions. A change in granuloma 
formation would change this and should lead to better 
intracellular killing of bacilli. Reduced numbers of bacilli in 
the sputum means that fewer are swallowed. Thus, some of 
the effects observed could be related to changing patterns of 
immune modulation by the gut-associated lymphoid 
tissues. 
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